Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non‐alcoholic fatty liver disease. (13th February 2021)

• Record Type: Journal Article
• Authors: Sciarrillo, Christina M.; Keirns, Bryant H.; Koemel, Nicholas A.; Anderson, Kendall L.; Emerson, Sam R.
• Is Part Of: Liver international. Volume 41:Number 5(2021)
• Page Start: 894
• Page End: 904
• Publication Date: 2021-02-13
• Subjects: bile acids and salts -- cholesterol 7‐alpha hydroxylase -- insulin resistance -- lipogenesis -- metabolic syndrome -- Non‐alcoholic fatty liver disease; Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.14802
• Languages: English
• ISSNs: 1478-3223

Abstract

Abstract: Non‐alcoholic fatty liver disease (NAFLD) is a spectrum of liver disease that is becoming more prevalent in concert with obesity and poor lifestyle habits. Although NAFLD is treatable via lifestyle modification in early stages, more advanced liver pathologies (eg non‐alcoholic steatohepatitis [NASH]) are harder to reverse. There is no Food and Drug Administration approved pharmacological treatment for NAFLD, and little research has been done to identify compounds that target key NAFLD mechanisms. Bile acids and bile acid receptors have been implicated in NAFLD pathogenesis and modulating bile acids and bile acid receptors has recently been targeted as a therapeutic treatment option for NAFLD. Fibroblast growth factor 19 (FGF19), a nutritionally regulated post‐prandial hormone, is a chief regulator of bile acid metabolism and an important player in lipid and carbohydrate metabolism, including key mechanisms of NAFLD pathogenesis. In this review, we discuss recent findings related to FGF19‐regulated processes involved in the pathogenesis of NAFLD. We summarize known and conjectural frameworks and limitations for the clinical application of FGF19‐targeted therapies as they relate to NAFLD.